FRET
By Ben Butkus
Biosearch Technologies said today that it has acquired worldwide rights from the University of Medicine and Dentistry of New Jersey to patents covering "non-FRET" nucleic acid probe technology.
The new test will be based on real-time PCR using fluorescence resonance energy transfer probes for detection.
The scientist has founded consulting firm Perpetual Genomics to license the technology, which would be a "true universal library" of extremely short FRET-based PCR probes that could allow manufacturers to sell probes fractionally and significantly reduce their cost.